Cell Line

Please note that an MTA needs to be signed prior to purchase of this product, we kindly request that you contact your local office. This product is provided at this price to private organisations.

The AC16 cell line, derived from human ventricular cells fused with SV40-transformed, uridine-auxotroph fibroblasts, showcases characteristics of cardiomyocytes, including the expression of transcription factors GATA4, MYCD, NFATc4, and contractile proteins like alpha- and beta-myosin heavy chain. These cells also express gap junction proteins connexin-43 and connexin-40, with functional gap junctions confirmed by dye-coupling studies. When the SV40 oncogene is silenced, AC16 transitions towards a differentiated state, marked by the expression of BMP2, indicative of cardiac differentiation. AC16 cells' ability to mimic cardiomyocyte behavior, including cessation of proliferation and formation of multinucleated syncytia under specific conditions, makes it a valuable model for cardiac research. It retains the genetic material of primary cardiomyocytes, allowing for studies on cardiac development and pathology in vitro, bridging gaps in understanding heart disease mechanisms and potential

ADAR1 Responsive Luciferase Reporter HEK293 Cell Line is a HEK293 cell line designed to respond to ADAR1 enzymatic activity. These cells were engineered to express an ADAR1 reporter construct comprised of an ADAR1 hairpin target with a stop codon (UAG) susceptible to ADAR1-mediated editing to tryptophan (UUG), located upstream of a firefly luciferase reporter (Figure 1). This cell line has been validated by comparing reporter activation after transfection with ADAR1 and ADAR2. This cell line has been used for the development of the constitutive ADAR1 expressing ADAR1 Activity Luciferase Reporter HEK293 Cell Line (#82239). The ADAR1 reporter construct is compromised of an ADAR1 hairpin targer with a stop codon (UAG) upstream of the sequence encoding luciferase. In the presence of ADAR1 activity, as in the case of transfection with ADAR1, adenine is converted into inosine encoding now the amino acid tryptophan (UUG) and enabling transcription and expression of luciferase. In the absence

ADAR1 Activity Luciferase Reporter HEK293 Cell Line is a HEK293 cell line designed to monitor the activity of ADAR1 (adenosine deaminase acting on RNA) enzyme. These cells were engineered to express ADAR1 (NM_001111.5) and an ADAR1 reporter construct comprised of an ADAR1 hairpin target with a stop codon (UAG) susceptible to ADAR1-mediated editing to tryptophan (UUG), located upstream of a firefly luciferase reporter. This cell line has been validated by comparing reporter activation to ADAR1 Responsive Luciferase Reporter HEK293 Cell Line (#82238) and in response to treatment with ADAR1 siRNA. The ADAR1 reporter construct is comprised of an ADAR1 hairpin target with a stop codon (UAG) upstream of the sequence encoding luciferase. In the absence of ADAR1, luciferase is not transcribed, and the cells show no luciferase activity. In the presence of ADAR1 activity, adenine is converted into inosine, encoding now the amino acid tryptophan (UUG) and enabling transcription and expression of

The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺and CD8⁺ T cells <u>with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783)</u>. These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺and CD8⁺ T cells <u>with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783)</u>. These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

The Membrane-Bound TNFα CHO Cell Line is a clonal CHO cell line stably expressing human membrane-bound TNFα (tumor necrosis factor alpha) driven by an EF1a promoter. The cells were generated by transduction with Membrane-Bound TNFα (mTNFα) Lentivirus (#78955).

Androgen Luciferase Reporter 22RV1 Cell Line is a human 22Rv1 cell line with a stably integrated Firefly luciferase reporter under the control of an androgen response element. This cell line monitors the activity of the androgen receptor signaling pathway. This cell line has been validated in cellular assays involving the inhibition of 5α-Dihydrotestosterone (5-DHT)-induced reporter activation by AR (androgen receptor) antagonists such as Enzalutamide, Bicalutamide, Mifepristone and ARCC-4.